SCHEMBL10138248

SCHEMBL10138248

CC(=O)c1ccc2cncc(-c3ccccc3)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 6/20 0.56
CDK8 P49336 6/20 0.49
CCNC P24863 5/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPT P10636 2/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MMP9 P14780 1/20 0.46
PLK4 O00444 2/20 0.46
AURKA O14965 2/20 0.46
DAPK3 O43293 2/20 0.46
CHEK2 O96017 2/20 0.46
CDK1 P06493 2/20 0.46
PIM1 P11309 2/20 0.46
PRKACA P17612 2/20 0.46
CDK2 P24941 2/20 0.46
MAPK9 P45984 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10138245 0.87 SLC22A12 (0.55) SLC22A12CDK8CCNCMMP9CYP11B1
SCHEMBL10138336 0.83 SLC22A12 (0.54) SLC22A12CDK8CCNC
SCHEMBL17837335 0.82 PRKCZ (0.59) SLC22A12CDK8CCNCMAPTSMN1; SMN2
SCHEMBL8755335 0.80 MAPT (0.58) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL12114721 0.76 CDK8 (0.46) SLC22A12CDK8CCNCALDH1A1KDM4E
SCHEMBL16211927 0.75 SLC22A12 (0.70) SLC22A12CDK8CCNCAURKACHEK2
SCHEMBL10138341 0.75 PARP10 (0.52) SLC22A12CHEK2CYP11B1CYP11B2
SCHEMBL10138319 0.74 SLC22A12 (0.54) SLC22A12CDK8CCNCKDM4ECHEK2
SCHEMBL8108129 0.74 PRKCZ (0.61) SLC22A12CDK8CCNCMMP9AURKB
SCHEMBL17981126 0.73 TDP1 (0.50) SLC22A12MAPTPLK4AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410273-B2 Cyclic compound having substituted phenyl group DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-04-02 US disclosed
US-20120040936-A1 CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040936-A1 CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP BMP2, BMP4, BMP6 SLC22A12 1300/4885CDK8 2959/4885CCNC 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.